Chemosensitizing activity of peptide from Lentinus squarrosulus (Mont.) on cisplatin-induced apoptosis in human lung cancer cells.
Adjuvants, Pharmaceutic
/ pharmacology
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Blotting, Western
Cell Line, Tumor
Cisplatin
/ pharmacology
Drug Synergism
Flow Cytometry
Humans
Lentinula
/ chemistry
Lung Neoplasms
/ drug therapy
Peptides
/ isolation & purification
Plant Extracts
/ pharmacology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 02 2021
18 02 2021
Historique:
received:
23
07
2020
accepted:
05
02
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The limitations of cisplatin, a standard chemotherapy for lung cancer, have been documented with serious adverse effects and drug resistance. To address the need for novel therapy, this study firstly reveals the potential of peptide from Lentinus squarrosulus (Mont.) as a chemotherapeutic adjuvant for cisplatin treatment. The purified peptide from L. squarrosulus aqueous extracts was obtained after eluting with 0.4 M NaCl through FPLC equipped with anion exchange column. Preincubation for 24 h with 5 µg/mL of the peptide at prior to treatment with 5 µM cisplatin significantly diminished %cell viability in various human lung cancer cells but not in human dermal papilla and proximal renal cells. Flow cytometry indicated the augmentation of cisplatin-induced apoptosis in lung cancer cells pretreated with peptide from L. squarrosulus. Preculture with the peptide dramatically inhibited colony formation in lung cancer cells derived after cisplatin treatment. Strong suppression on integrin-mediated survival was evidenced with the diminution of integrins (β1, β3, β5, α5, αV) and down-stream signals (p-FAK/FAK, p-Src/Src, p-Akt/Akt) consequence with alteration of p53, Bax, Blc-2 and Mcl-1 in cisplatin-treated lung cancer cells preincubated with peptide from L. squarrosulus. These results support the development of L. squarrosulus peptide as a novel combined chemotherapy with cisplatin for lung cancer treatment.
Identifiants
pubmed: 33603033
doi: 10.1038/s41598-021-83606-1
pii: 10.1038/s41598-021-83606-1
pmc: PMC7892851
doi:
Substances chimiques
Adjuvants, Pharmaceutic
0
Antineoplastic Agents
0
Peptides
0
Plant Extracts
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4060Références
Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).
pubmed: 30100160
doi: 10.1016/j.ejca.2018.07.005
Patel, N., Adatia, R., Mellemgaard, A., Jack, R. & Møller, H. Variation in the use of chemotherapy in lung cancer. Br. J. Cancer 96, 886–890 (2007).
pubmed: 17342091
pmcid: 2360093
doi: 10.1038/sj.bjc.6603659
Ettinger, D. S. et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Ne. 15, 504–535 (2017).
doi: 10.6004/jnccn.2017.0050
Besse, B. & Le Chevalier, T. Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. Oncology (Williston Park) 23, 520–527 (2009).
Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018).
pubmed: 29364287
doi: 10.1038/nature25183
d’Amato, T. A., Landreneau, R. J., McKenna, R. J., Santos, R. S. & Parker, R. J. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann. Thorac. Surg. 81, 440–447 (2006).
pubmed: 16427828
doi: 10.1016/j.athoracsur.2005.08.037
Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2, 2490–2518 (2010).
doi: 10.3390/toxins2112490
Sun, C. Y., Zhang, Q. Y., Zheng, G. J. & Feng, B. Phytochemicals: Current strategy to sensitize cancer cells to cisplatin. Biomed. Pharmacother. 110, 518–527 (2019).
pubmed: 30530287
doi: 10.1016/j.biopha.2018.12.010
de Oliveira Júnior, R. G. et al. Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. Fitoterapia 129, 383–400 (2018).
pubmed: 29476786
doi: 10.1016/j.fitote.2018.02.025
Han, J. Y. et al. The relationship between cisplatin-induced apoptosis and p53, Bcl-2 and Bax expression in human lung cancer cells. Korean J. Intern. Med. 14, 42–52 (1999).
pubmed: 10063313
pmcid: 4531897
doi: 10.3904/kjim.1999.14.1.42
Mehta, S. V., Shukla, S. N. & Vora, H. H. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3. Neoplasma 60, 666–675 (2013).
pubmed: 23906301
doi: 10.4149/neo_2013_085
Zhang, J. et al. Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: A meta-analysis and systemic review. Onco. Targets Ther. 8, 3361–3369 (2015).
pubmed: 26604794
pmcid: 4655977
doi: 10.2147/OTT.S89275
Kumar Biswas, S., Huang, J., Persaud, S. & Basu, A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol. Cancer Ther. 3, 327–334 (2004).
pubmed: 15026553
doi: 10.1158/1535-7163.327.3.3
Thomas, L. W., Lam, C. & Edwards, S. W. Mcl-1; the molecular regulation of protein function. FEBS. Lett. 584, 2981–2989 (2010).
pubmed: 20540941
doi: 10.1016/j.febslet.2010.05.061
Zhang, F. et al. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. Cancer Biol. Ther. 18, 606–615 (2017).
pubmed: 28686074
pmcid: 5653185
doi: 10.1080/15384047.2017.1345391
Milas, I. et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin. Cancer Res. 9, 1070–1076 (2003).
pubmed: 12631609
Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Ther. 146, 132–149 (2015).
pubmed: 25316657
doi: 10.1016/j.pharmthera.2014.10.001
Bergmann, S. et al. Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells. J. Cell Sci. 122, 256–267 (2009).
pubmed: 19118218
doi: 10.1242/jcs.035600
Dingemans, A. M. et al. Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol. Cancer 9, 152 (2010).
pubmed: 20565758
pmcid: 2895598
doi: 10.1186/1476-4598-9-152
Wayner, E. A., Orlando, R. A. & Cheresh, D. A. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113, 919–929 (1991).
pubmed: 1709170
doi: 10.1083/jcb.113.4.919
Maiuthed, A. & Chanvorachote, P. Cisplatin at sub-toxic levels mediates integrin switch in lung cancer cells. Anticancer Res. 34, 7111–7117 (2014).
pubmed: 25503138
Santos, A. R. et al. β1 integrin-focal adhesion kinase (FAK) signaling modulates retinal ganglion cell (RGC) survival. PLoS ONE 7, e48332 (2012).
pubmed: 23118988
pmcid: 3485184
doi: 10.1371/journal.pone.0048332
Nguyen, D. M. et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway. J. Thorac. Cardiovasc. Surg. 125, 1132–1142 (2003).
pubmed: 12771887
doi: 10.1067/mtc.2003.180
Aksorn, N. & Chanvorachote, P. Integrin as a molecular target for anti-cancer approaches in lung cancer. Anticancer Res. 39, 541–548 (2019).
pubmed: 30711928
doi: 10.21873/anticanres.13146
Raab-Westphal, S., Marshall, J. F. & Goodman, S. L. Integrins as therapeutic targets: Successes and cancers. Cancers (Basel) 9, 110 (2017).
doi: 10.3390/cancers9090110
Kim, M. Y. et al. Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells. J. Biomed. Res. 30, 217–224 (2016).
pubmed: 27533932
pmcid: 4885170
Kallifatidis, G., Hoy, J. J. & Lokeshwar, B. L. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin. Cancer Biol. 40–41, 160–169 (2016).
pubmed: 27370570
pmcid: 5067195
doi: 10.1016/j.semcancer.2016.06.003
Friedman, M. Mushroom polysaccharides: Chemistry and antiobesity, antidiabetes, anticancer, and antibiotic properties in cells, rodents, and humans. Foods 5, 80 (2016).
pmcid: 5302426
doi: 10.3390/foods5040080
Prateep, A., Sumkhemthong, S., Suksomtip, M., Chanvorachote, P. & Chaotham, C. Peptides extracted from edible mushroom: Lentinus squarrosulus induces apoptosis in human lung cancer cells. Pharm. Biol. 55, 1792–1799 (2017).
pubmed: 28532227
pmcid: 6130440
doi: 10.1080/13880209.2017.1325913
Wu, J. et al. Identification of microRNA-mRNA networks involved in cisplatin-induced renal tubular epithelial cells injury. Eur. J. Pharmacol. 851, 1–12 (2019).
pubmed: 30768982
doi: 10.1016/j.ejphar.2019.02.015
Ma, X., Yan, L., Zhu, Q. & Shao, F. Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway. PLoS ONE 12, e0171612 (2017).
pubmed: 28182789
pmcid: 5300759
doi: 10.1371/journal.pone.0171612
Botchkarev, V. A. Molecular mechanisms of chemotherapy-induced hair loss. J. Investig. Dermatol. Symp. Proc. 8, 72–75 (2003).
pubmed: 12894998
doi: 10.1046/j.1523-1747.2003.12175.x
Puchsaka, P., Chaotham, C. & Chanvorachote, P. α-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin β1/β3 downregulation. Int. J. Oncol. 49, 1445–1456 (2016).
pubmed: 27431988
doi: 10.3892/ijo.2016.3624
Rieger, A. M., Nelson, K. L., Konowalchuk, J. D. & Barreda, D. R. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J. Vis. Exp. 50, 2597 (2011).
Wlodkowic, D., Skommer, J. & Darzynkiewicz, Z. Flow cytometry-based apoptosis detection. Methods Mol. Biol. 559, 19–32 (2009).
pubmed: 19609746
doi: 10.1007/978-1-60327-017-5_2
Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315–2319 (2006).
pubmed: 17406473
doi: 10.1038/nprot.2006.339
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F. & Correia, I. J. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol. Bioeng. 116, 206–226 (2018).
pubmed: 30367820
doi: 10.1002/bit.26845
Zanoni, M. et al. 3D tumor spheroid models for in vitro therapeutic screening: A systematic approach to enhance the biological relevance of data obtained. Sci. Rep. 6, 19103 (2016).
pubmed: 26752500
pmcid: 4707510
doi: 10.1038/srep19103
Fennell, D. A. et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat. Rev. 44, 42–50 (2016).
pubmed: 26866673
doi: 10.1016/j.ctrv.2016.01.003
Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364–378 (2014).
pubmed: 25058905
doi: 10.1016/j.ejphar.2014.07.025
pmcid: 4146684
Matsumoto, M., Nakajima, W., Seike, M., Gemma, A. & Tanaka, N. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem. Biophys. Res. Commun. 473, 490–496 (2016).
pubmed: 26996126
doi: 10.1016/j.bbrc.2016.03.053
Hata, A. N., Engelman, J. A. & Faber, A. C. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 5, 475–487 (2015).
pubmed: 25895919
pmcid: 4727530
doi: 10.1158/2159-8290.CD-15-0011
Gibbons, D. L., Byers, L. A. & Kurie, J. M. Smoking, p53 mutation, and lung cancer. Mol. Cancer Res. 12, 3–13 (2014).
pubmed: 24442106
pmcid: 3925633
doi: 10.1158/1541-7786.MCR-13-0539
Millard, M., Odde, S. & Neamati, N. Integrin targeted therapeutics. Theranostics 1, 154–188 (2011).
pubmed: 21547158
pmcid: 3086618
doi: 10.7150/thno/v01p0154
Chakrabarti, S., Jahandideh, F. & Wu, J. Food-derived bioactive peptides on inflammation and oxidative stress. Biomed. Res. Int. 2014, 608979 (2014).
pubmed: 24527452
pmcid: 3914560
doi: 10.1155/2014/608979
Aoudjit, F. & Vuori, K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 283181 (2012).
pubmed: 22567280
pmcid: 3332161
Mantovani, F., Collavin, L. & Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26, 199–212 (2019).
pubmed: 30538286
doi: 10.1038/s41418-018-0246-9
Symonds, J. M., Ohm, A. M., Tan, A. C. & Reyland, M. E. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget 7, 17905–17919 (2016).
pubmed: 26918447
pmcid: 4951259
doi: 10.18632/oncotarget.7560
Hamidi, H. & Ivaska, J. Every step of the way: Integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533–548 (2018).
pubmed: 30002479
pmcid: 6629548
doi: 10.1038/s41568-018-0038-z
Seguin, L. et al. An integrin β
pubmed: 24747441
pmcid: 4105198
doi: 10.1038/ncb2953
Arosio, D., Manzoni, L., Corno, C. & Perego, P. Integrin-targeted peptide- and peptidomimetic-drug conjugates for the treatment of tumors. Recent Pat. Anticancer Drug Discov. 12, 148–168 (2017).
pubmed: 28164756
doi: 10.2174/1574892812666170203151930
Sancey, L. et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol. Ther. 17, 837–843 (2009).
pubmed: 19259068
doi: 10.1038/mt.2009.29
Thomas, M. et al. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J. Biol. Chem. 285, 23842–23849 (2010).
pubmed: 20519501
pmcid: 2911308
doi: 10.1074/jbc.M109.097543
Deslouches, B. & Di, Y. P. Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications. Oncotarget 8, 46635–46651 (2017).
pubmed: 28422728
pmcid: 5542299
doi: 10.18632/oncotarget.16743
Akekawatchai, C., Roytrakul, S., Phaonakrop, N., Jaresitthikunchai, J. & Jitrapakdee, S. Proteomic analysis of the anoikis-resistant human breast cancer cell lines. Methods Mol. Biol. 2138, 185–193 (2020).
pubmed: 32219748
doi: 10.1007/978-1-0716-0471-7_11
Ekert, J. E. et al. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro–implication for drug development. PLoS ONE 9, e92248 (2014).
pubmed: 24638075
pmcid: 3956916
doi: 10.1371/journal.pone.0092248